These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1160 related articles for article (PubMed ID: 31953310)
21. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353 [TBL] [Abstract][Full Text] [Related]
22. A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Romaniello D; Mazzeo L; Mancini M; Marrocco I; Noronha A; Kreitman M; Srivastava S; Ghosh S; Lindzen M; Salame TM; Onn A; Bar J; Yarden Y Clin Cancer Res; 2018 Nov; 24(22):5610-5621. PubMed ID: 29967248 [No Abstract] [Full Text] [Related]
23. Landscape of Acquired Resistance to Osimertinib in Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958 [TBL] [Abstract][Full Text] [Related]
24. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway. Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025 [TBL] [Abstract][Full Text] [Related]
25. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983 [TBL] [Abstract][Full Text] [Related]
26. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929 [TBL] [Abstract][Full Text] [Related]
27. Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor-Tolerant Cells in NSCLC Patient-Derived Xenografts. Zhou CQ; Li A; Ri K; Sultan AS; Ren H Cancer Res Commun; 2024 Sep; 4(9):2308-2319. PubMed ID: 39041204 [TBL] [Abstract][Full Text] [Related]
32. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation. Yang YM; Jang Y; Lee SH; Kang B; Lim SM Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387 [TBL] [Abstract][Full Text] [Related]
33. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988 [TBL] [Abstract][Full Text] [Related]
34. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735 [TBL] [Abstract][Full Text] [Related]
35. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations. Li XF; Shen WZ; Jin X; Ren P; Zhang J Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer. Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun SY J Exp Med; 2024 Nov; 221(11):. PubMed ID: 39297884 [TBL] [Abstract][Full Text] [Related]
37. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332 [TBL] [Abstract][Full Text] [Related]
38. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. Yun J; Hong MH; Kim SY; Park CW; Kim S; Yun MR; Kang HN; Pyo KH; Lee SS; Koh JS; Song HJ; Kim DK; Lee YS; Oh SW; Choi S; Kim HR; Cho BC Clin Cancer Res; 2019 Apr; 25(8):2575-2587. PubMed ID: 30670498 [TBL] [Abstract][Full Text] [Related]
39. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272 [TBL] [Abstract][Full Text] [Related]
40. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer. Park W; Wei S; Xie CL; Han JH; Kim BS; Kim B; Jin JS; Yang ES; Cho MK; Ryu D; Yang HX; Bae SJ; Ha KT Exp Mol Med; 2024 May; 56(5):1137-1149. PubMed ID: 38689087 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]